Anacura and RIC combine R&D and GMP activities, launch anaRIC biologics
With the purpose of supporting customers throughout their entire biological drug development process, GMP specialist Anacura and the R&D-focused RIC have initiated a collaboration under the moniker anaRIC biologics.
anaRIC biologics is a CRO specialized in the analysis of complex, biological compounds, such as antibodies, proteins and peptides. These innovative products differ drastically from classical, small molecules and require a different set of skills to analyze. With 15 years of GMP and 30 years of R&D experience, anaRIC biologics is able to support this rapidly growing market segment throughout the entire drug development process.
Koen Sandra, scientific director of the Research Institute for Chromatography (RIC), said, “Given their complexity and heterogeneity there is a clear need for analytical expertise in the domain of biological molecules. Different phases during development translate into different needs. By combining RIC’s flexible and innovative R&D with Anacura’s standardized and stable GMP environment we are able to create a highly complementary collaboration accentuating our strengths."
Griet Nuytinck, managing director at Anacura, said, “Whether you are talking about product lead selection, manufacturing or analytical testing, choosing the right partner to bring your biological product to market is of strategic importance. Through our R&D/GMP partnership, anaRIC biologics becomes your reference CRO for analytics of biological molecules from discovery to marketing."